About The Study: The addition of dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, to standard care for critically ill patients and acute organ dysfunction did not improve clinical outcomes; however, confidence intervals were wide and could not exclude relevant benefits or harms for dapagliflozin.
Corresponding Author: To contact the corresponding author, Fernando G. Zampieri, M.D., Ph.D., email fernando.zampieri@einstein.br.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2024.10510)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being presented at the Critical Care Reviews Meeting 2024.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.10510?guestAccessKey=231fc6e9-5de6-4abf-a59c-5d4c47270746&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=061424
Journal
JAMA